宫颈癌是一个重大的全球健康问题，特别是在低收入和中等收入国家。感染艾滋病毒（WLWH）的女性不仅由于对高危人乳头瘤病毒（HPV）感染的易感性增加和免疫状态受损而面临更高的宫颈癌风险，而且据报道死亡率也更高。因此，预防、最佳筛查、使用高效抗逆转录病毒疗法 (HAART) 以及早期获得治疗对于这一人群至关重要。虽然宫颈癌国际指南规定不应对 WLWH 进行治疗差异，但有证据表明，这部分患者群体对肿瘤内科医生、放射肿瘤科医生和外科肿瘤科医生的决策构成了挑战。本综述总结了 WLWH 和浸润性宫颈癌不同治疗策略的现有证据，并强调了 WLWH 筛查和预防宫颈癌时需要特别考虑的必要性。版权所有 © 2024 Elsevier B.V. 保留所有权利。

Cervical cancer is a significant global health issue, particularly in low- and middle-income countries. Women living with HIV (WLWH) are not only at higher risk of cervical cancer due to their increased susceptibility to high-risk human papillomavirus (HPV) infection and compromised immune status, but also higher mortality rates have been reported. Therefore, prevention, optimal screening, use of highly active antiretroviral therapy (HAART), and early access to treatment are of utmost importance in this population. While international guidelines for cervical cancer state no treatment differences should be made for WLWH, there is evidence that this population of patients represents a challenge in decision-making for medical oncologists, radiation oncologists, and surgical oncologists. This review summarizes the available evidence on the different treatment strategies for WLWH and invasive cervical cancer and highlights the need for special considerations in screening andprevention of cervical cancer in WLWH.Copyright © 2024 Elsevier B.V. All rights reserved.